DarioHealth Corp. Stock News

NEW YORK--(BUSINESS WIRE)---- $DRIO #GLP1--PESG Releases Report: In a healthcare market brimming with potential, DarioHealth Corp. (Nasdaq: DRIO)* is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it seems DarioHealth's multi-condition digital health platform and its accelerating financial trajectory may position it...

Significant participation from existing shareholders and accredited healthcare investors, which the company believes underscores confidence in its strategy Financing supports execution of long-term growth initiatives focused on high-margin, scalable recurring revenues across B2B (Business-to-Business) and pharma channels NEW YORK , Jan. 21, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ...

NEW YORK--(BUSINESS WIRE)--Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 billion annually by 2030. The company's latest move expands its GLP-1 offering with prescribing capabilities, positioning Dario to capture a larger share of this lucrative space as demand for medical wei...

New collaboration enhances Dario's comprehensive GLP-1 offering with virtual physician management to meet growing demand from employers covering weight-loss medications, opening new revenue streams in direct-to-consumer and pharma channels NEW YORK , Jan. 14, 2025 /PRNewswire/ -- January 14, 2025 -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital heal...

Company expects to reach an estimated total of 25 new client signings in 2024, representing an approximate 35% growth in client base compared to 2023 NEW YORK , Nov. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of four contracts with self-insured employers that are expected to go l...

DarioHealth Corp. (NASDAQ:DRIO ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Third Quarter 2024 Results Call. [Operator Instructions] This call is being recorded ...

Demonstrated strong improvements in financial performance and business momentum. Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.

The new platform services subscription contract with a top six U.S. pharma client marks a pivotal shift in Dario's pharma channel, transitioning the business model from milestone-based to recurring service subscription fees by expanding engagement with payors and pharmacy benefit managers (PBMs) NEW YORK , Nov. 4, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"),...